| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Phacoemulsification | 24 | 2021 | 69 | 5.380 |
Why?
|
| Lenses, Intraocular | 25 | 2021 | 96 | 5.000 |
Why?
|
| Cataract | 16 | 2021 | 134 | 3.760 |
Why?
|
| Visual Acuity | 26 | 2020 | 236 | 3.740 |
Why?
|
| Lens Implantation, Intraocular | 22 | 2021 | 152 | 3.730 |
Why?
|
| Keratomileusis, Laser In Situ | 14 | 2021 | 35 | 2.830 |
Why?
|
| Refraction, Ocular | 13 | 2021 | 61 | 2.830 |
Why?
|
| Astigmatism | 5 | 2019 | 17 | 2.190 |
Why?
|
| Myopia | 6 | 2019 | 27 | 1.640 |
Why?
|
| Cornea | 12 | 2019 | 76 | 1.500 |
Why?
|
| Aberrometry | 2 | 2020 | 5 | 1.400 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2019 | 52 | 1.260 |
Why?
|
| Postoperative Complications | 17 | 2021 | 1615 | 1.250 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 7 | 2006 | 240 | 1.150 |
Why?
|
| Ketorolac Tromethamine | 7 | 2006 | 16 | 1.080 |
Why?
|
| Intraocular Pressure | 11 | 2020 | 143 | 1.030 |
Why?
|
| Surgical Flaps | 8 | 2007 | 120 | 1.000 |
Why?
|
| Punctal Plugs | 2 | 2021 | 2 | 0.950 |
Why?
|
| Prospective Studies | 24 | 2021 | 3705 | 0.940 |
Why?
|
| Refractive Surgical Procedures | 6 | 2007 | 16 | 0.860 |
Why?
|
| Keratitis | 6 | 2006 | 20 | 0.840 |
Why?
|
| Anterior Chamber | 5 | 2018 | 20 | 0.820 |
Why?
|
| Cataract Extraction | 13 | 2008 | 127 | 0.810 |
Why?
|
| Ophthalmic Solutions | 10 | 2014 | 39 | 0.720 |
Why?
|
| Intraoperative Care | 2 | 2020 | 91 | 0.710 |
Why?
|
| Vision, Binocular | 2 | 2020 | 30 | 0.710 |
Why?
|
| Endothelium, Corneal | 8 | 2011 | 20 | 0.690 |
Why?
|
| Emmetropia | 1 | 2019 | 2 | 0.690 |
Why?
|
| Lens Capsule, Crystalline | 12 | 2009 | 39 | 0.680 |
Why?
|
| Uveitis, Anterior | 5 | 2011 | 15 | 0.680 |
Why?
|
| Prosthesis Design | 9 | 2020 | 301 | 0.650 |
Why?
|
| Glucocorticoids | 5 | 2018 | 222 | 0.630 |
Why?
|
| Contrast Sensitivity | 3 | 2007 | 28 | 0.610 |
Why?
|
| Prednisolone | 5 | 2018 | 23 | 0.610 |
Why?
|
| Corneal Stroma | 5 | 2004 | 20 | 0.580 |
Why?
|
| Intraoperative Complications | 3 | 2009 | 129 | 0.570 |
Why?
|
| Humans | 67 | 2021 | 68618 | 0.570 |
Why?
|
| Iris | 2 | 2009 | 27 | 0.550 |
Why?
|
| Middle Aged | 36 | 2020 | 21147 | 0.540 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 3 | 2004 | 19 | 0.520 |
Why?
|
| Ophthalmology | 3 | 2005 | 39 | 0.510 |
Why?
|
| Aged | 30 | 2020 | 14862 | 0.490 |
Why?
|
| Aged, 80 and over | 16 | 2020 | 4848 | 0.480 |
Why?
|
| Double-Blind Method | 10 | 2021 | 1738 | 0.440 |
Why?
|
| Dry Eye Syndromes | 3 | 2014 | 12 | 0.440 |
Why?
|
| Endophthalmitis | 2 | 2018 | 15 | 0.430 |
Why?
|
| Male | 38 | 2020 | 37321 | 0.420 |
Why?
|
| Treatment Outcome | 16 | 2021 | 7029 | 0.410 |
Why?
|
| Refractive Errors | 3 | 2007 | 24 | 0.410 |
Why?
|
| Female | 38 | 2020 | 38074 | 0.410 |
Why?
|
| Benzeneacetamides | 2 | 2021 | 11 | 0.380 |
Why?
|
| Patient Satisfaction | 4 | 2009 | 378 | 0.360 |
Why?
|
| Corneal Ulcer | 3 | 2007 | 10 | 0.360 |
Why?
|
| Photorefractive Keratectomy | 4 | 2007 | 12 | 0.360 |
Why?
|
| Microspheres | 1 | 2010 | 59 | 0.360 |
Why?
|
| Pupil | 4 | 2007 | 51 | 0.360 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2005 | 504 | 0.350 |
Why?
|
| Ultrasonic Therapy | 4 | 2008 | 19 | 0.350 |
Why?
|
| Inflammation | 6 | 2021 | 1030 | 0.340 |
Why?
|
| Disease Models, Animal | 5 | 2006 | 2550 | 0.340 |
Why?
|
| Iris Diseases | 1 | 2009 | 8 | 0.330 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2009 | 32 | 0.330 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2009 | 20 | 0.330 |
Why?
|
| Staphylococcus aureus | 3 | 2007 | 175 | 0.330 |
Why?
|
| Acrylic Resins | 3 | 2005 | 48 | 0.320 |
Why?
|
| Glaucoma, Open-Angle | 3 | 2020 | 19 | 0.320 |
Why?
|
| Sensation | 2 | 2005 | 49 | 0.310 |
Why?
|
| Sulfonamides | 1 | 2009 | 141 | 0.310 |
Why?
|
| Staphylococcal Infections | 2 | 2007 | 156 | 0.300 |
Why?
|
| Trabecular Meshwork | 2 | 2020 | 22 | 0.300 |
Why?
|
| Eye Infections, Bacterial | 2 | 2007 | 15 | 0.290 |
Why?
|
| Rabbits | 12 | 2006 | 509 | 0.290 |
Why?
|
| Pseudophakia | 3 | 2020 | 27 | 0.290 |
Why?
|
| Vision Disorders | 2 | 2007 | 94 | 0.290 |
Why?
|
| Nedocromil | 2 | 2004 | 7 | 0.290 |
Why?
|
| Adult | 19 | 2021 | 21403 | 0.290 |
Why?
|
| Retrospective Studies | 9 | 2021 | 7277 | 0.280 |
Why?
|
| Color Perception | 1 | 2005 | 9 | 0.270 |
Why?
|
| Fluoroquinolones | 1 | 2006 | 49 | 0.260 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2006 | 62 | 0.260 |
Why?
|
| Eye Pain | 2 | 2021 | 3 | 0.240 |
Why?
|
| Phenylacetates | 2 | 2021 | 18 | 0.240 |
Why?
|
| Optics and Photonics | 3 | 2021 | 29 | 0.240 |
Why?
|
| Biometry | 3 | 2021 | 72 | 0.230 |
Why?
|
| Cyclopentolate | 1 | 2003 | 3 | 0.230 |
Why?
|
| Mydriatics | 1 | 2003 | 4 | 0.230 |
Why?
|
| Drug Residues | 1 | 2003 | 6 | 0.230 |
Why?
|
| Corneal Pachymetry | 3 | 2019 | 5 | 0.230 |
Why?
|
| Polychondritis, Relapsing | 1 | 2003 | 3 | 0.230 |
Why?
|
| Detergents | 1 | 2003 | 34 | 0.230 |
Why?
|
| Carnivora | 1 | 2003 | 2 | 0.220 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2003 | 2 | 0.220 |
Why?
|
| Follow-Up Studies | 7 | 2020 | 3259 | 0.220 |
Why?
|
| Corneal Injuries | 1 | 2003 | 4 | 0.220 |
Why?
|
| Eyelids | 1 | 2003 | 11 | 0.220 |
Why?
|
| Mycobacterium chelonae | 1 | 2003 | 9 | 0.220 |
Why?
|
| Stents | 2 | 2020 | 657 | 0.220 |
Why?
|
| Bites and Stings | 1 | 2003 | 34 | 0.220 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2003 | 37 | 0.210 |
Why?
|
| Candidiasis | 1 | 2002 | 39 | 0.210 |
Why?
|
| Pain, Postoperative | 1 | 2004 | 214 | 0.200 |
Why?
|
| Surveys and Questionnaires | 6 | 2020 | 2800 | 0.200 |
Why?
|
| Multifocal Intraocular Lenses | 1 | 2020 | 1 | 0.190 |
Why?
|
| Trabeculectomy | 1 | 2020 | 5 | 0.180 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2020 | 3 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 2 | 2006 | 1026 | 0.170 |
Why?
|
| Androstadienes | 2 | 2014 | 41 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 114 | 0.170 |
Why?
|
| Planning Techniques | 1 | 2018 | 16 | 0.160 |
Why?
|
| Pilot Projects | 2 | 2021 | 1342 | 0.160 |
Why?
|
| Equipment Design | 4 | 2019 | 500 | 0.160 |
Why?
|
| Miotics | 1 | 1998 | 1 | 0.150 |
Why?
|
| Carbachol | 1 | 1998 | 34 | 0.150 |
Why?
|
| Tolmetin | 1 | 1997 | 1 | 0.150 |
Why?
|
| Miosis | 1 | 1997 | 1 | 0.150 |
Why?
|
| Lasers, Excimer | 4 | 2007 | 10 | 0.150 |
Why?
|
| Tromethamine | 1 | 1997 | 4 | 0.150 |
Why?
|
| Flurbiprofen | 1 | 1997 | 3 | 0.150 |
Why?
|
| Administration, Topical | 3 | 2006 | 111 | 0.150 |
Why?
|
| Dexamethasone | 1 | 2018 | 150 | 0.150 |
Why?
|
| Lens, Crystalline | 5 | 1992 | 39 | 0.150 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1997 | 73 | 0.150 |
Why?
|
| Cell Count | 7 | 2011 | 248 | 0.140 |
Why?
|
| Staining and Labeling | 3 | 2005 | 144 | 0.140 |
Why?
|
| Safety | 5 | 2004 | 145 | 0.140 |
Why?
|
| Animals | 15 | 2010 | 20881 | 0.140 |
Why?
|
| Spain | 1 | 2016 | 34 | 0.140 |
Why?
|
| Cloprostenol | 1 | 2014 | 1 | 0.120 |
Why?
|
| Laser Therapy | 2 | 2009 | 54 | 0.120 |
Why?
|
| Anti-Allergic Agents | 1 | 2014 | 27 | 0.120 |
Why?
|
| Microsurgery | 1 | 2014 | 46 | 0.120 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2004 | 133 | 0.120 |
Why?
|
| Preoperative Care | 3 | 2007 | 275 | 0.120 |
Why?
|
| Cyclosporine | 1 | 2014 | 121 | 0.120 |
Why?
|
| Visual Fields | 3 | 2020 | 41 | 0.110 |
Why?
|
| Sclera | 1 | 1993 | 8 | 0.110 |
Why?
|
| Suture Techniques | 1 | 1993 | 75 | 0.110 |
Why?
|
| Lipopolysaccharides | 3 | 2004 | 455 | 0.110 |
Why?
|
| Postoperative Period | 3 | 2011 | 238 | 0.100 |
Why?
|
| Drug Therapy, Combination | 4 | 2014 | 649 | 0.100 |
Why?
|
| Societies, Medical | 2 | 2005 | 403 | 0.100 |
Why?
|
| Fluprednisolone | 1 | 2011 | 2 | 0.100 |
Why?
|
| Corneal Edema | 1 | 2011 | 4 | 0.100 |
Why?
|
| Time Factors | 7 | 2020 | 4655 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 514 | 0.090 |
Why?
|
| Torsion, Mechanical | 1 | 2010 | 1 | 0.090 |
Why?
|
| Suction | 1 | 2010 | 33 | 0.090 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 498 | 0.090 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2010 | 54 | 0.090 |
Why?
|
| Herpes Zoster Ophthalmicus | 2 | 2005 | 4 | 0.090 |
Why?
|
| Lasers, Solid-State | 1 | 2009 | 8 | 0.090 |
Why?
|
| Syndrome | 2 | 2009 | 255 | 0.080 |
Why?
|
| Risk Factors | 3 | 2009 | 5731 | 0.080 |
Why?
|
| Video Recording | 1 | 2010 | 145 | 0.080 |
Why?
|
| Hyperopia | 1 | 2009 | 14 | 0.080 |
Why?
|
| Eye Diseases | 2 | 2003 | 38 | 0.080 |
Why?
|
| Incidence | 2 | 2009 | 1603 | 0.080 |
Why?
|
| Keratoplasty, Penetrating | 2 | 2005 | 6 | 0.080 |
Why?
|
| Swine | 1 | 2010 | 672 | 0.080 |
Why?
|
| Cadaver | 3 | 2004 | 136 | 0.080 |
Why?
|
| Computer Simulation | 1 | 2011 | 706 | 0.080 |
Why?
|
| Foreign-Body Migration | 1 | 1987 | 38 | 0.070 |
Why?
|
| Microscopy, Electron, Scanning | 4 | 2002 | 236 | 0.070 |
Why?
|
| Acrylates | 1 | 2007 | 17 | 0.070 |
Why?
|
| Ofloxacin | 2 | 2007 | 15 | 0.070 |
Why?
|
| Foreign Bodies | 1 | 1987 | 58 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2014 | 1040 | 0.070 |
Why?
|
| Methicillin Resistance | 1 | 2007 | 45 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2006 | 47 | 0.070 |
Why?
|
| Chickenpox | 1 | 2006 | 14 | 0.070 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2006 | 3 | 0.070 |
Why?
|
| Ophthalmoplegia | 1 | 2006 | 20 | 0.070 |
Why?
|
| Conjunctivitis | 1 | 2006 | 6 | 0.070 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2006 | 15 | 0.070 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2006 | 18 | 0.070 |
Why?
|
| Instillation, Drug | 1 | 2006 | 15 | 0.070 |
Why?
|
| Bacteriological Techniques | 2 | 2003 | 49 | 0.070 |
Why?
|
| Quality of Life | 2 | 2009 | 1515 | 0.070 |
Why?
|
| Ciliary Body | 3 | 2003 | 52 | 0.070 |
Why?
|
| Temporal Arteries | 1 | 2005 | 7 | 0.070 |
Why?
|
| Giant Cell Arteritis | 1 | 2005 | 10 | 0.070 |
Why?
|
| Capsulorhexis | 1 | 2005 | 18 | 0.070 |
Why?
|
| Tears | 1 | 2005 | 9 | 0.070 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2005 | 6 | 0.070 |
Why?
|
| Eye Infections, Fungal | 1 | 2005 | 7 | 0.070 |
Why?
|
| Conjunctiva | 1 | 2005 | 16 | 0.070 |
Why?
|
| Disease Transmission, Infectious | 1 | 2005 | 25 | 0.060 |
Why?
|
| Cryptococcosis | 1 | 2005 | 28 | 0.060 |
Why?
|
| Keratectomy, Subepithelial, Laser-Assisted | 1 | 2005 | 3 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2005 | 249 | 0.060 |
Why?
|
| Body Weights and Measures | 1 | 2004 | 11 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2006 | 453 | 0.060 |
Why?
|
| Geography | 1 | 2004 | 80 | 0.060 |
Why?
|
| Postoperative Care | 2 | 2004 | 163 | 0.060 |
Why?
|
| Eye Injuries | 1 | 2004 | 18 | 0.060 |
Why?
|
| Analgesia | 1 | 2004 | 58 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2005 | 195 | 0.060 |
Why?
|
| Corneal Neovascularization | 1 | 2003 | 6 | 0.060 |
Why?
|
| Porphyrins | 1 | 2003 | 15 | 0.060 |
Why?
|
| Rabies Vaccines | 1 | 2003 | 4 | 0.060 |
Why?
|
| Rabies | 1 | 2003 | 5 | 0.060 |
Why?
|
| Facial Injuries | 1 | 2003 | 10 | 0.060 |
Why?
|
| Clarithromycin | 1 | 2003 | 11 | 0.060 |
Why?
|
| Stainless Steel | 1 | 2003 | 31 | 0.060 |
Why?
|
| Amikacin | 1 | 2003 | 13 | 0.060 |
Why?
|
| Mycobacterium Infections | 1 | 2003 | 13 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2004 | 137 | 0.060 |
Why?
|
| Rupture | 1 | 2003 | 29 | 0.060 |
Why?
|
| Sensation Disorders | 1 | 2003 | 14 | 0.060 |
Why?
|
| Photosensitizing Agents | 1 | 2003 | 32 | 0.060 |
Why?
|
| Indicators and Reagents | 1 | 2003 | 63 | 0.060 |
Why?
|
| Solutions | 1 | 2003 | 115 | 0.060 |
Why?
|
| Ciprofloxacin | 1 | 2003 | 30 | 0.060 |
Why?
|
| Pain Measurement | 1 | 2004 | 328 | 0.050 |
Why?
|
| Biological Factors | 1 | 2003 | 11 | 0.050 |
Why?
|
| Tobramycin | 1 | 2003 | 38 | 0.050 |
Why?
|
| Ear Diseases | 1 | 2003 | 37 | 0.050 |
Why?
|
| Corneal Diseases | 1 | 2002 | 12 | 0.050 |
Why?
|
| Photochemotherapy | 1 | 2003 | 59 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2003 | 152 | 0.050 |
Why?
|
| Eyeglasses | 2 | 2020 | 11 | 0.050 |
Why?
|
| Health Surveys | 1 | 2005 | 489 | 0.050 |
Why?
|
| Titanium | 1 | 2003 | 118 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 351 | 0.050 |
Why?
|
| Water | 1 | 2003 | 230 | 0.050 |
Why?
|
| United States | 2 | 2005 | 7367 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2002 | 108 | 0.050 |
Why?
|
| Vaccination | 1 | 2003 | 189 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2003 | 166 | 0.050 |
Why?
|
| Prosthesis Failure | 1 | 2002 | 130 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 629 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2002 | 431 | 0.040 |
Why?
|
| Loteprednol Etabonate | 2 | 2014 | 4 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2002 | 234 | 0.040 |
Why?
|
| Administration, Ophthalmic | 1 | 2018 | 3 | 0.040 |
Why?
|
| Biocompatible Materials | 2 | 1992 | 247 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 2077 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2018 | 82 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 2006 | 1140 | 0.040 |
Why?
|
| Ocular Hypertension | 1 | 1998 | 43 | 0.040 |
Why?
|
| Corneal Transplantation | 1 | 1997 | 3 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 1173 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 236 | 0.030 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 1996 | 32 | 0.030 |
Why?
|
| Organ Preservation | 1 | 1996 | 69 | 0.030 |
Why?
|
| Anterior Eye Segment | 2 | 2003 | 13 | 0.030 |
Why?
|
| Adolescent | 2 | 2009 | 8912 | 0.030 |
Why?
|
| Travoprost | 1 | 2014 | 1 | 0.030 |
Why?
|
| Tonometry, Ocular | 1 | 2014 | 11 | 0.030 |
Why?
|
| Teaching | 1 | 1996 | 169 | 0.030 |
Why?
|
| Aqueous Humor | 1 | 2014 | 51 | 0.030 |
Why?
|
| Presbyopia | 1 | 1992 | 1 | 0.030 |
Why?
|
| Contact Lenses, Hydrophilic | 1 | 1992 | 5 | 0.030 |
Why?
|
| Reoperation | 2 | 2005 | 467 | 0.030 |
Why?
|
| Polyurethanes | 1 | 1992 | 21 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 951 | 0.020 |
Why?
|
| Research Design | 1 | 1996 | 729 | 0.020 |
Why?
|
| Pulse Therapy, Drug | 1 | 2011 | 5 | 0.020 |
Why?
|
| Cavernous Sinus | 1 | 1991 | 10 | 0.020 |
Why?
|
| Anesthetics | 1 | 1991 | 30 | 0.020 |
Why?
|
| Injections | 1 | 1991 | 119 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 4 | 1992 | 219 | 0.020 |
Why?
|
| Silicones | 1 | 1989 | 32 | 0.020 |
Why?
|
| Tropicamide | 1 | 1989 | 1 | 0.020 |
Why?
|
| Phenylephrine | 1 | 1989 | 61 | 0.020 |
Why?
|
| Bibliometrics | 1 | 2009 | 25 | 0.020 |
Why?
|
| Therapeutic Irrigation | 1 | 1989 | 63 | 0.020 |
Why?
|
| Global Health | 1 | 2009 | 136 | 0.020 |
Why?
|
| Foreign-Body Reaction | 2 | 2002 | 24 | 0.020 |
Why?
|
| Methicillin | 1 | 2007 | 11 | 0.020 |
Why?
|
| Necrosis | 1 | 1987 | 239 | 0.020 |
Why?
|
| Vancomycin | 1 | 2007 | 60 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1987 | 157 | 0.020 |
Why?
|
| Ophthalmic Nerve | 1 | 2005 | 4 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2006 | 164 | 0.020 |
Why?
|
| Acyclovir | 1 | 2005 | 38 | 0.020 |
Why?
|
| Valine | 1 | 2005 | 43 | 0.020 |
Why?
|
| Health Personnel | 1 | 2007 | 286 | 0.010 |
Why?
|
| Equipment Safety | 1 | 2004 | 50 | 0.010 |
Why?
|
| Biopsy | 1 | 2005 | 540 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2005 | 211 | 0.010 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2003 | 18 | 0.010 |
Why?
|
| Bodily Secretions | 1 | 2003 | 3 | 0.010 |
Why?
|
| Meibomian Glands | 1 | 2003 | 4 | 0.010 |
Why?
|
| Soaps | 1 | 2003 | 5 | 0.010 |
Why?
|
| Exotoxins | 1 | 2003 | 4 | 0.010 |
Why?
|
| Lasers | 1 | 2003 | 61 | 0.010 |
Why?
|
| Povidone-Iodine | 1 | 2003 | 16 | 0.010 |
Why?
|
| Laser Coagulation | 1 | 2002 | 8 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 215 | 0.010 |
Why?
|
| Cryotherapy | 1 | 2002 | 36 | 0.010 |
Why?
|
| Electron Probe Microanalysis | 1 | 2002 | 16 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 252 | 0.010 |
Why?
|
| Device Removal | 1 | 2002 | 100 | 0.010 |
Why?
|
| Cell Survival | 1 | 2004 | 901 | 0.010 |
Why?
|
| Cats | 2 | 1992 | 292 | 0.010 |
Why?
|
| Silicone Elastomers | 1 | 2000 | 17 | 0.010 |
Why?
|
| Polymethyl Methacrylate | 1 | 2000 | 31 | 0.010 |
Why?
|
| Methylmethacrylates | 2 | 1989 | 14 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2000 | 765 | 0.010 |
Why?
|
| Cell Movement | 1 | 2000 | 630 | 0.010 |
Why?
|
| Coloring Agents | 1 | 1997 | 66 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 1997 | 122 | 0.010 |
Why?
|
| Teaching Materials | 1 | 1996 | 16 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1997 | 261 | 0.010 |
Why?
|
| Cell Death | 1 | 1997 | 329 | 0.010 |
Why?
|
| Eye | 1 | 1996 | 89 | 0.010 |
Why?
|
| Child | 1 | 2006 | 6405 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 1996 | 136 | 0.010 |
Why?
|
| Education, Medical | 1 | 1996 | 147 | 0.010 |
Why?
|
| Depth Perception | 1 | 1992 | 12 | 0.010 |
Why?
|
| Refractometry | 1 | 1992 | 23 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1992 | 144 | 0.010 |
Why?
|
| Tensile Strength | 1 | 1992 | 90 | 0.010 |
Why?
|
| Biodegradation, Environmental | 1 | 1992 | 92 | 0.010 |
Why?
|
| Muscles | 1 | 1992 | 158 | 0.010 |
Why?
|
| Oculomotor Nerve | 1 | 1991 | 1 | 0.010 |
Why?
|
| Trochlear Nerve | 1 | 1991 | 3 | 0.010 |
Why?
|
| Abducens Nerve | 1 | 1991 | 3 | 0.010 |
Why?
|
| Cranial Nerve Diseases | 1 | 1991 | 14 | 0.010 |
Why?
|
| Trigeminal Nerve | 1 | 1991 | 22 | 0.010 |
Why?
|
| Orbit | 1 | 1991 | 30 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 1992 | 159 | 0.010 |
Why?
|
| Materials Testing | 1 | 1992 | 263 | 0.010 |
Why?
|
| Internship and Residency | 1 | 1996 | 596 | 0.010 |
Why?
|
| Hardness | 1 | 1989 | 20 | 0.010 |
Why?
|
| Skin | 1 | 1992 | 451 | 0.010 |
Why?
|
| Uvea | 1 | 1988 | 2 | 0.000 |
Why?
|